CSIMarket
 
Ventrus Biosciences Inc  (VTUS)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Ventrus Biosciences Inc
Ventrus Biosciences Inc. is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for gastrointestinal disorders. The company's mission is to address unmet medical needs in the field of gastroenterology by utilizing innovative drug delivery technologies. Ventrus Biosciences is dedicated to improving the lives of patients suffering from conditions such as hemorrhoids, anal fissures, and inflammatory bowel disease. The company is committed to advancing its pipeline of products, conducting clinical trials, and bringing effective and safe treatments to market.


   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Pharmacyte Biotech Inc

The evolving company from the Biotechnology and Pharmaceuticals market the PMCB reported the fiscal third quarter of 2024, numbers

The Biotechnology and Pharmaceuticals industry insiders start to interpret the third quarter of 2024 earnings. Presently those insiders monitor operating loss of $-1.868946 million, from the company, as it hasn't stated any revenue thus far, for the own November to January 31 2024 reporting period.

Adverum Biotechnologies Inc

The Biotechnology and Pharmaceuticals company caused great surprise for the stock market, posting a relevant growth in fiscal time-frame closing December 31 2023 with operating deficit of $-26.158 million

The shareholders have not expected any moderations at the top-line all over the earnings season of the October to December 31 2023 at the ADVM. Yet, they consider the company's operating deficit which was at $-26.158 million, in the same period.

Zeo Scientifix Inc

Very balanced growth for BPSR during the November to January 31 2024 three months

For the financial span ending January 31 2024 BPSR increased a deficit per share of $-0.17 per share compare to $0.00 a year ago and from $0.00 per share from the previous reporting period. The Revenue advanced by 7.828 % to $1.15 million from $1.07 million in the comparable reporting period a year ago and sequentially revenue fell by -18.84 % from $1.42 million.

Cyclo Therapeutics Inc

CYTH Sees Impressive Revenue Surge and Deficit Reduction in Q4 2023

Cyclo Therapeutics Inc, a Biotechnology and Pharmaceuticals company, has shown positive growth in the fourth quarter of 2023, despite industry-wide challenges. In its December 31, 2023 report, the company reported a significant revenue rise of 66.699% to $0.31 million. This increase in revenue has helped the company reduce its losses to $-0.18 per share, down from $-0.48 per share in the same reporting season the previous year.
Unlike many other entities in the Biotechnology and Pharmaceuticals sectors, which are experiencing declining top-line and receding transactions, Cyclo Therapeutics Inc has managed to shine in the fourth quarter. This is a positive development for the company, as it signifies its ability to navigate obstacles and maintain growth.

Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc Reports Operating Deficit of $-18.2 Million in Fourth Quarter of 2023

In the world of biotechnology and pharmaceuticals, Calidi Biotherapeutics Inc has recently announced its financial results for the fourth quarter of 2023. The company reported an operating deficit of $-18.246049 million, a significant increase from the operating deficit of $-2.714765 million in the fourth quarter of 2022.
The net deficit for the financial period ending December 31, 2023, was reported at $-20.699 million, a substantial increase from $-2.587 million in the previous year. Despite these losses, the company did not report any revenue for the financial year 2023, with a bottom-line of $-29.22 million.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com